Advanced search
Publication Cover
Expert Review of Hematology Volume 7, 2014 - Issue 5
Submit an article Journal homepage
899
Views
19
CrossRef citations to date
0
Altmetric
Drug Profiles

Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B

Jonathan M DucoreDivision of Hematology and Oncology, University of California Davis Medical Center, Suite 3016, 4501 X Street, Sacramento, CA 95817, USA
,
Maricel G MiguelinoDivision of Hematology and Oncology, University of California Davis Medical Center, Suite 3016, 4501 X Street, Sacramento, CA 95817, USA
&
Jerry S PowellCorrespondence[email protected]
Pages 559-571 | Published online: 21 Aug 2014

Citations (19)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Cassandra P. Wang, Guy Young & Courtney D. Thornburg. (2021) Safety evaluation of emicizumab prophylaxis in individuals with haemophilia A. Expert Opinion on Drug Safety 20:4, pages 387-396.
Read now
Roland E. Kontermann. (2016) Half-life extended biotherapeutics. Expert Opinion on Biological Therapy 16:7, pages 903-915.
Read now
Marcus E Carr & Bartholomew J Tortella. (2015) Emerging and future therapies for hemophilia. Journal of Blood Medicine 6, pages 245-255.
Read now
Peter Norman. (2015) Orphan drug approvals of 2014: Europe and the United States. Expert Opinion on Orphan Drugs 3:4, pages 445-455.
Read now

Articles from other publishers (15)

Marilyn Jean Manco-Johnson & Beth Boulden Warren. (2022) Long-term prophylaxis: what are our options and how to define success?. Hematology 2022:1, pages 579-585.
Crossref
V. N. Konstantinova, T. A. Andreeva & A. V. Kim. (2021) Prospects for the use of prolonged concentrates of blood clotting factor IX in the treatment of hemophilia B. Russian Journal of Pediatric Hematology and Oncology 7:4, pages 56-61.
Crossref
Kuldeep Rajpoot, Muktika Tekade, Mukesh Chandra Sharma, Nagaraja Sreeharsha, Anita Sharma & Rakesh K. Tekade. 2020. The Future of Pharmaceutical Product Development and Research. The Future of Pharmaceutical Product Development and Research 447 482 .
Babbal, Adivitiya, Shilpa Mohanty & Yogender Pal Khasa. 2019. High Value Fermentation Products. High Value Fermentation Products 225 263 .
Romel Menacho-Melgar, John S. Decker, Jennifer N. Hennigan & Michael D. Lynch. (2019) A review of lipidation in the development of advanced protein and peptide therapeutics. Journal of Controlled Release 295, pages 1-12.
Crossref
C. Wang & G. Young. (2018) Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B. Haemophilia 24:3, pages 414-419.
Crossref
Carole Heath & Dean Pettit. 2018. Challenges in Protein Product Development. Challenges in Protein Product Development 545 558 .
Daniel Dixon, Serguei Tchessalov & Bakul Bhatnagar. 2018. Challenges in Protein Product Development. Challenges in Protein Product Development 407 439 .
T. Preijers, H.C.A.M. Hazendonk, K. Fijnvandraat, F.W.G. Leebeek, M.H. Cnossen & R.A.A. Mathôt. (2017) In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients. Journal of Thrombosis and Haemostasis 15:9, pages 1737-1746.
Crossref
A. M. Clough, J. A. Gilreath, J. P. McPherson, N. C. Link, G. M. Rodgers & D. Nance. (2017) Implementation of a recombinant factor IX Fc fusion protein extended-infusion desensitization protocol. Haemophilia 23:3, pages e227-e230.
Crossref
D. Levin, H.A.D. Lagassé, E. Burch, S. Strome, S. Tan, H. Jiang, Z.E. Sauna & B. Golding. (2017) Modulating immunogenicity of factor IX by fusion to an immunoglobulin Fc domain: a study using a hemophilia B mouse model. Journal of Thrombosis and Haemostasis 15:4, pages 721-734.
Crossref
Hanns-Christian Mahler & Roman Mathäs. 2017. Process Scale Purification of Antibodies. Process Scale Purification of Antibodies 673 697 .
Rowena C. Punzalan & Jerome L. Gottschall. (2016) Use and Future Investigations of Recombinant and Plasma-Derived Coagulation and Anticoagulant Products in the Neonate. Transfusion Medicine Reviews 30:4, pages 189-196.
Crossref
Nikolaos Sousos, Eleni Gavriilaki, Sofia Vakalopoulou & Vasileia Garipidou. (2016) Understanding cardiovascular risk in hemophilia: A step towards prevention and management. Thrombosis Research 140, pages 14-21.
Crossref
Thomas Hilberg. 2016. Therapie und Prävention Durch Sport, Band 3. Therapie und Prävention Durch Sport, Band 3 101 111 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.